TFF Pharmaceuticals, Inc.

FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. The Company expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about February 16, 2025. The removal of the Common Stock from Nasdaq will be effective 10 days after the filing of the Form 25. The Company has made no arrangements for the listing or quotation of its Common Stock on any other exchange, market or quotation medium. The withdrawal of the Common Stock from listing and registration is being undertaken in connection with the planned the liquidation and dissolution of the Company. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding our plans to wind down our operations or other statements not of historical fact. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: the timing, progress and results of our planned wind down; general market conditions; and other risks described in TFF Pharmaceuticals' filings with the Securities and Exchange Commission under the heading "Risk Factors". All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. TFF Pharmaceuticals undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. SOURCE TFF Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Plus, news about Bavarian Nordic, Nuvectis Pharma, Flashpoint Therapeutics, Sparian Biosciences and TFF Pharmaceuticals: Vitalli Bio axes Daewoong asset: Vitalli, founded by Joe Jimenez’s Aditum Bio , plans to terminate its licensing agreement for an autoimmune disease drug developed by Daewoong Pharmaceutical, according to a regulatory filing . The deal was worth up to $477 million for Daewoong. Vitalli still has the option for two additional candidates from Daewoong, the company said. Jimenez declined to comment, citing “confidentiality with our partners.” — Kyle LaHucik Alector takes out $50M loan: The money from Hercules Capital will help fund two studies: a Phase 3 for latozinemab in frontotemporal dementia, and a Phase 2 for AL002 in early Alzheimer’s disease. Alector will receive $10 million immediately and can get another $15 million at any time before June 30, 2026. The final $25 million will be available at Hercules’ approval. — Max Gelman Bavarian Nordic secures $340M in mpox, smallpox vaccine orders for 2025: The company told investors that the additional mpox orders contributed to its decision to upgrade its financial guidance for this year. Nearly three million doses of the company’s mpox vaccine MVA-BN have been pledged to Africa so far. — Anna Brown Nuvectis Pharma’s stock dives on Phase 1b data: Of 11 evaluable patients with late-line ovarian cancer who took NXP800, a GCN2 kinase activator, only one patient achieved an unconfirmed partial response, the company said . Nuvectis tested multiple dosing regimens, including different amounts and once- or twice-a-day. Nuvectis’ stock $NVCT closed 46% lower on Thursday. — Max Gelman Flashpoint Therapeutics partners with Saudi Arabia, Northwestern University: The biotech is teaming up with the King Abdullah International Medical Research Center in Riyadh in a $50 million effort to establish a new nanomedicine research center, which will receive the money over five years. Flashpoint also said it expanded its IP to include “150 issued patents and patent applications” through a deal with Northwestern. — Max Gelman Sparian Biosciences’ $19.5M NIH grant: The New York biotech got a five-year grant from the National Institute on Drug Abuse to help develop an opiate use disorder drug through Phase 1. It got a similar grant last year for another drug that aims to treat stimulant use disorder. — Kyle LaHucik TFF Pharmaceuticals to wind down: The Fort Worth, TX-based biotech let go all employees and will shut down . It had been working on dry powder formulations for drugs, including for lung transplant rejection, flu and Covid. It had $4.4 million in cash and equivalents at the end of June. — Kyle LaHucik

FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in their wind-down phases. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding our plans to wind down our operations or other statements not of historical fact. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: the timing, progress and results of our planned wind down; general market conditions; and other risks described in TFF Pharmaceuticals’ filings with the Securities and Exchange Commission under the heading “Risk Factors”. All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. TFF Pharmaceuticals undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. Company Contact:Verdolino & Lowey, P.C.124 Washington Street, Suite 101Foxboro, MA. 02035Phone - 508-543-1720